Sharp increase in HALO’s short interest leads to surge in days-to-cover ratio

Investors can speculate about the future of a stock by watching how its insiders buy and sell stocks. Halozyme Therapeutics Inc shares valued at $150,481 were sold by Connaughton Bernadette on Oct 01 ’25. At $75.24 per share, Connaughton Bernadette sold 2,000 shares. The insider’s holdings dropped to 44,952 shares worth approximately $3.22 million following the completion of this transaction.

Also, Helen Torley purchased 136,569 shares, netting a total of over 10,015,970 in proceeds.

Before that, LaBrosse Nicole had sold 2,227 shares from its account. In a trade valued at $173,584, the SVP, CHIEF FINANCIAL OFFICER traded Halozyme Therapeutics Inc shares for $77.95 each. Upon closing the transaction, the insider’s holdings decreased to 2,227 shares, worth approximately $1.58 million.

As published in a research note from Morgan Stanley on August 06, 2025, Halozyme Therapeutics Inc [HALO] has been rated up from an Equal-weight to an Overweight and the price target has been revised to $75. As of May 14, 2025, Morgan Stanley has decreased its “an Overweight” rating to a “an Equal-weight” for HALO. Earlier on May 13, 2025, Leerink Partners downgraded its rating. Their new recommendation was “an Underperform” for HALO stock which previously was a “a Market perform”.

Analyzing HALO Stock Performance

On last trading session, Halozyme Therapeutics Inc [NASDAQ: HALO] plunged -4.34% to $71.69. The stock’s lowest price that day was $69.7, but it reached a high of $75.5 in the same session. During the last five days, there has been a drop of approximately -3.08%. Over the course of the year, Halozyme Therapeutics Inc shares have jumped approximately 25.24%. Shares of the company reached a 52-week high of $79.50 on 09/23/25 and a 52-week low of $47.50 on 05/14/25.

Support And Resistance Levels for Halozyme Therapeutics Inc (HALO)

According to the 24-hour chart, there is a support level at 69.09, which, if violated, would cause prices to drop to 66.50. In the upper region, resistance lies at 74.89. The next price resistance is at 78.10. RSI (Relative Strength Index) is 42.82 on the 14-day chart, showing neutral technical sentiment.

Is Halozyme Therapeutics Inc subject to short interest?

Stocks of Halozyme Therapeutics Inc saw a sharp rise in short interest on 2025-09-15 jumping by 1.21 million shares to 11.78 million. Data from Yahoo Finance shows that the short interest on 2025-08-15 was 10.57 million shares. A jump of 10.26% in short interest reflects a negative sentiment towards the stock. Despite the fact that short shares comprise just 6.03 of the overall float, the days-to-cover ratio (short ratio) jumped to 6.03.

Which companies own the most shares of Halozyme Therapeutics Inc (HALO)?

In terms of Halozyme Therapeutics Inc share price expectations, FactSet research, analysts set an average price target of 76 in the next 12 months, up nearly 1.41% from the previous closing price of $74.94. Analysts anticipate Halozyme Therapeutics Inc stock to reach 90 by 2025, with the lowest price target being 62. In spite of this, 7 analysts ranked Halozyme Therapeutics Inc stock as Buy at the end of 2025. On October 07, 2024, Wells Fargo assigned a price target of “an Equal weight” to the stock and downgraded coverage with a $62.

Most Popular

Knox Daily
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.